| 2025-01-10 | -2.44 % |
|
| 2025-01-07 | +0.04 % |
|
| 2025-01-06 | -1.37 % |
|
| 2025-01-03 | +0.91 % |
|
| 2025-01-02 | +0.43 % |
|
| 2024-12-27 | -1.05 % |
|
| 2024-12-19 | -0.05 % |
|
| 2024-12-17 | +0.02 % |
|
| 2024-12-16 | -1.37 % |
|
| 2024-12-09 | -0.06 % |
|
| 2024-12-06 | -0.15 % |
|
| 2024-12-04 | -0.46 % |
|
| 2024-12-02 | |
|
| 2024-11-27 | +0.69 % |
|
| 2024-11-26 | -0.08 % |
|
| 2024-11-25 | -0.53 % |
|
| 2024-11-22 | +1.73 % |
|
| 2024-11-21 | +0.75 % |
|
| 2024-11-20 | -1.05 % |
|
| 2024-11-19 | -2.96 % |
|
| 2024-11-18 | +0.07 % |
|
| 2024-10-31 | -1.38 % |
|
| 2024-10-30 | +0.2 % |
|
| 2024-10-29 | -0.31 % |
|
| 2024-10-28 | +0.01 % |
|
| 2024-10-25 | -0.44 % |
|
| 2024-10-23 | +1.26 % |
|
| 2024-10-22 | +0.1 % |
|
| 2024-10-21 | -1.31 % |
|
| 2024-10-18 | +2.73 % |
|
| 2024-10-17 | -0.22 % |
|
| 2024-10-16 | +0.17 % |
|
| 2024-10-15 | -0.19 % |
|
| 2024-10-14 | +0.73 % |
|
| 2024-10-11 | +0.57 % |
|
| 2024-10-10 | +0.57 % |
|
| 2024-10-09 | +0.24 % |
- The article discusses recent institutional investment activities in McDonald's Co. (NYSE:MCD) stock, which saw a slight increase of 0.24%, highlighting various changes in holdings by investors and analysts' price targets.
The increase in Medtronic (MDT) stock is not directly addressed in the article; however, general market trends, positive earnings outlooks, or strategic moves by the company could be influencing factors behind stock price rises.
- Medtronic (MDT) stock rose by 0.24% recently, likely due to strong quarterly earnings that exceeded analyst expectations, as well as increased price targets and favorable ratings from multiple research firms.
- Medtronic (MDT) stock rose 0.24% following significant increases in institutional investments, positive analyst ratings updates, and successful earnings reports that exceeded expectations.
The stock's rise can be attributed to substantial buying activity from institutional investors, positive revisions from analysts regarding price targets, and continued revenue and earnings growth as reported in their quarterly earnings.
- Medtronic (MDT) stock saw a slight increase of 0.24% following a reported reduction in holdings by Partnership Wealth Management LLC, which may indicate market adjustments and investor sentiments amidst ongoing changes in institutional investments.
- Medtronic (MDT) stock increased by 0.24% due to a combination of positive analyst reports raising price targets and the company's strong earnings performance that exceeded expectations during the last quarter.
|
| 2024-10-08 | +1.26 % |
|
| 2024-10-04 | +0.56 % |
|
| 2024-10-03 | -1.51 % |
|
| 2024-10-02 | -0.98 % |
|
| 2024-10-01 | -0.03 % |
|
| 2024-09-26 | +0.07 % |
|
| 2024-09-25 | -0.41 % |
|
| 2024-09-24 | -0.11 % |
|
| 2024-09-20 | -0.15 % |
|
| 2024-09-17 | -1.64 % |
|
| 2024-09-13 | |
|
| 2024-09-10 | +0.41 % |
|
| 2024-09-06 | +0.56 % |
- Medtronic (MDT) stock rose 0.56% due to increased options trading, positive quarterly earnings results that exceeded analyst expectations, and favorable upgrades in price targets from multiple equity research analysts.
- The Medtronic (MDT) stock increased by 0.56% following positive market sentiment driven by its collaboration with Orchestra BioMed, which has received a Buy rating and a favorable price target from analysts, indicating confidence in the company's innovative approaches and potential for success in product development.
- The article discusses the increasing global burden of gastrointestinal cancers, noting a rise in incidence and death rates, particularly for colorectal, pancreatic, and liver cancers from metabolic dysfunction.
Medtronic (MDT) stock likely rose by 0.56% due to positive market sentiment or investor confidence influenced by its involvement in medical technologies related to cancer treatment and management, as suggested by the mention of the company's research grants in the context of gastrointestinal cancer.
- Medtronic (MDT) stock rose by 0.56% likely due to increased investing activity from institutional investors, positive analyst upgrades on target prices, and a recent earnings report that exceeded expectations, indicating financial stability and growth potential.
|
| 2024-09-03 | +0.43 % |
|
| 2024-08-15 | +2.34 % |
|
| 2024-08-13 | +1.33 % |
|
| 2024-08-12 | -1.04 % |
|
| 2024-08-08 | +1.38 % |
|
| 2024-08-06 | +0.56 % |
|
| 2024-08-05 | -1.45 % |
|
| 2024-07-24 | +0.72 % |
|
| 2024-07-18 | -0.06 % |
|
| 2024-07-17 | +4.05 % |
- The article discusses high-yield dividend stocks, such as Medtronic (MDT), and emphasizes the importance of analyzing stocks beyond just their yield profiles to ensure they are sound investments; Medtronic's stock went up last night, likely due to its 10-year history of consecutive dividend growth, diverse line of healthcare products providing stable cash flows, strong market position, record of innovation, and a good entry point for a high-yielding stock with a strong balance sheet.
- Summary: Thoroughbred Financial Services LLC acquired a new stake in Medtronic plc (NYSE:MDT) in the 1st quarter, leading to a 4.05% increase in the company's stock price, with several other hedge funds also adding stakes in Medtronic, and research analysts providing varying ratings and target prices for the stock.
Medtronic (MDT) stock went up as Thoroughbred Financial Services LLC and several other hedge funds acquired new stakes in the company, leading to increased investor confidence and positive analyst ratings and target price revisions for the stock.
|
| 2024-07-16 | +1.32 % |
- Summary: Baird adjusted its outlook on Medtronic (MDT) by lowering its price target to $82.00 but maintained a Neutral rating, anticipating that the company's first-quarter fiscal year 2025 revenue and adjusted earnings per share (EPS) will exceed consensus expectations, driven by stable top-line growth, operational improvements, and supply chain initiatives, despite caution surrounding future EPS growth, with the stock rising 1.32% last night.
Medtronic's stock went up due to positive developments in its top-line growth, operational improvements, and supply chain initiatives that are stabilizing year-over-year operating margin compression and showing potential for margin expansion and EPS growth, despite caution by Baird surrounding the sustainability of long-term EPS growth acceleration.
- Truist Securities revised Medtronic (MDT) stock's price target to $85 from $88, maintaining a Hold rating, citing its slightly lower earnings prospects relative to industry peers and applying a 15 times multiple to the projected EPS for 2025, hinting that the stock went up due to the potential for Medtronic to demonstrate improved growth trajectory or outperform earnings expectations.
- The article discusses the importance of boards in appointing the right CEO by examining examples of poor leadership at public companies, such as Home Depot, and highlighting the need for better succession planning processes to avoid negative impacts on businesses. Medtronic (MDT) stock went up by 1.32% last night, likely due to positive market trends or company-specific news that influenced investor sentiment.
|
| 2024-07-15 | -1.12 % |
|
| 2024-07-11 | +1.31 % |
|
